Wilex AG | Cash Flow

Fiscal year is December-November. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
5,040.30
5,700.80
6,551.60
6,389.00
10,970.20
11,672
Depreciation, Depletion & Amortization
1,715.90
403.00
311.60
279.90
406.20
369
Other Funds
52.40
709.50
2,406.40
105.60
2,790.90
490.80
Funds from Operations
3,272.10
4,588.30
3,833.70
6,003.50
10,236.90
10,812.20
Changes in Working Capital
11,180.30
2,031.80
962.40
531.40
2,296.90
829
Net Operating Cash Flow
14,452.40
6,620.10
4,796.00
6,534.90
7,940.00
9,983.20
Capital Expenditures
172.20
195.80
207.00
537.90
416.10
Net Investing Cash Flow
172.20
195.80
207.00
537.90
416.10
Issuance/Reduction of Debt, Net
224.30
38.40
23.90
3,748.00
-
Net Financing Cash Flow
224.30
38.40
4,101.90
10,335.00
34,180.60
Net Change in Cash
14,443.30
6,723.30
891.10
3,268.70
25,806.70
Free Cash Flow
14,596.30
6,815.90
4,995.10
7,058.50
8,340.40
Deferred Taxes & Investment Tax Credit
-
-
-
-
3,118.00
-
Change in Capital Stock
-
-
4,125.80
6,586.90
34,180.60
Exchange Rate Effect
405.60
131.10
10.00
6.50
17.80

About Wilex

View Profile
Address
Schriesheimer Strasse 101
Ladenburg Baden Wuerttemberg 68526
Germany
Employees -
Website http://heidelberg-pharma.com
Updated 07/08/2019
Heidelberg Pharma AG engages in the development of diagnostic and therapeutic products for the detection and targeted treatment of various types of cancer. It operates through the following segments: Customer Specific Research (Cx), Diagnostics (Dx), andTherapeutics (Rx). The Customer Specific Research segment includes preclinical and Antibody Drug Conjugate technology services.